MGMT and neoplasm: Methylation status of the MGMT promoter as assessed by MS-PCR as well as the MGMT immunoprofile was available from 178 tumor samples (27 metastases of renal cell carcinoma, 39 of breast carcinoma, 36 of lung carcinoma, and 76 of malignant melanoma).